{
  "abstract": "Background and Importance PrEP has established itself as a fundamental HIV prevention strategy in high-risk populations.Aim and Objectives The primary objective is to evaluate the efficacy and adherence to PrEP. Secondary objectives include characterising the clinical profile of patients, verifying eligibility criteria, analysing comorbidities, examining the incidence of STIs, and determining the safety of treatment.Material and Methods Observational and retrospective study of PrEP users between January 2022 and December 2024. Variables included demographic data, eligibility criteria, comorbidities, analytical and microbiological follow-up, adherence, interactions, and tolerance.Results 47 users, mostly male (95.7%), with a median age of 35 years (24-57). All reported sex with men; 6.38% engaged in prostitution, and 14.89% practiced chem-sex. Common comorbidities were dyslipidaemia (10.64%), hypertension (4.26%), and diabetes (4.26%). 12% percent had nephropathy before starting PrEP. Serum creatinine (0.95 ± 0.46 g/dL) and phosphorus (3.43 ± 1.76 g/dL) remained stable (p > 0.05). No patient had a history of neoplasms, liver disease, or major cardiovascular events. Charlson index was <1; Profund index identified social vulnerability in 4.26%. 97.87% met criteria to start PrEP. 53.19% had at least one STI in the last year, notably gonorrhoea (43.33%), chlamydia (20%), and syphilis (20%). A downward STI trend was noted: anal swabs from 6.38% to 8.7%, throat swabs from 8.51% to 0%, urethral swabs from 6.38% to 4.35%, total positive STIs from 12.77% to 9.38%. Swab performance decreased (anal 4.26% vs. 13.04%; nasopharyngeal 8.51% vs. 8.7%). Time from infectious disease consult to prophylaxis start was 12.11 ± 8.63 days. Treatment persistence averaged 14.74 ± 10.5 months. Average adherence was 90.66%, with 23.4% lost to follow-up due to low adherence (14.89%), missing labs (6.38%), or missed visits (2.13%). PrEP discontinuation was 8.51%. Home treatment was reported by 63.3%. Polypharmacy and drug interactions (NSAIDs) occurred in 10.64%. Adverse effects in 42.55% included gastrointestinal discomfort (27.66%), insomnia (6.38%), headache (4.26%), facial tingling (2.13%), and nightmares (2.13%).Conclusion and Relevance This study confirms the effectiveness and safety of PrEP in preventing HIV in a high-risk population, with high but improvable adherence. The incidence of STIs highlights the importance of optimising microbiological monitoring and sex education. Adverse effects were minor and manageable.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "R Varela Fernández"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "S Llamas-Lorenzana"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Internal Medicine Deparment, León, Spain"
      ],
      "name": "P Dios-Díez"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Internal Medicine Deparment, León, Spain"
      ],
      "name": "A Romero Calvo"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Internal Medicine Deparment, León, Spain"
      ],
      "name": "P Ortiz De Urbina Fernández"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "FV Ana"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "N Garcia Mieres"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "L Ortega Valin"
    },
    {
      "affiliations": [
        "León University Health Care Complex Caule, Hospital Pharmacy Service, León, Spain"
      ],
      "name": "JJ Ortiz De Urbina González"
    }
  ],
  "title": "5PSQ-008 Comprehensive evaluation of HIV pre-exposure prophylaxis in clinical practice: a multivariable approach to the determinants of use",
  "uid": "c04f892e-7c37-51cd-84d2-6004bf40cd75"
}